FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2031240327> ?p ?o ?g. }

• W2031240327 endingPage "305" @default.
• W2031240327 startingPage "300" @default.
• W2031240327 abstract "Lapatinib is the first dual tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2/neu) and epidermal growth factor receptor (EGFR). The present study evaluated the efficacy and tolerability of the combination of lapatinib and capecitabine in patients with metastatic breast cancer (MBC) who progressed after therapy with trastuzumab, a taxane and/or anthracycline. A total of 203 patients with a median age of 48 years (range: 25–82 years) were evaluated retrospectively in 11 centres between September 2007 and May 2011. All the patients had HER2-positive MBC progressing after trastuzumab and chemotherapy including an anthracycline and/or taxane. All patients were treated with the combination of lapatinib (1250 mg/day, continuously) and capecitabine (2000 mg/m2 on days 1 through 14 of a 21-day cycle). Data on demographics, clinical outcome, and toxicity were collected for descriptive analyses. The median follow-up was 10·7 months (range: 1–40 months). An overall response rate (ORR) of 33·4% was achieved including 7 complete responses (CR, 3·4%), 61 partial responses (PR, 30·0%), and 44 stable disease (37·9%). Clinical benefit rate of 71·3% was achieved. Median progression-free survival (PFS) was 7 months (95% CI: 6–10 months), with a median overall survival (OS) of 15 months (95% CI: 12–18 months). The most common side effects were hand–foot syndrome (46·8%), nausea (42·3%), fatigue (42·2%), anorexia (38·5%), diarrhea (31·5%), and rash (29·6%). Grade 3–4 toxicities were identified as hand foot syndrome (7·9%), diarrhea (6·9%), fatigue (5·9%), and rash (5·4%). There were no symptomatic cardiac events. Lapatinib and capecitabine combination therapy is effective and well tolerated in patients with MBC who had progressive disease after trastuzumab, taxane, and/or anthracycline therapy, as evidenced by this retrospective evaluation. Toxicity was mild to moderate with low grade 3–4 toxicity." @default.
• W2031240327 created "2016-06-24" @default.
• W2031240327 creator A5016011343 @default.
• W2031240327 creator A5016695561 @default.
• W2031240327 creator A5028500628 @default.
• W2031240327 creator A5033702098 @default.
• W2031240327 creator A5033726162 @default.
• W2031240327 creator A5033820961 @default.
• W2031240327 creator A5037337957 @default.
• W2031240327 creator A5038018761 @default.
• W2031240327 creator A5044367089 @default.
• W2031240327 creator A5044883162 @default.
• W2031240327 creator A5045696675 @default.
• W2031240327 creator A5064627647 @default.
• W2031240327 creator A5074710198 @default.
• W2031240327 creator A5075330567 @default.
• W2031240327 creator A5075580269 @default.
• W2031240327 creator A5077193503 @default.
• W2031240327 creator A5082587759 @default.
• W2031240327 date "2013-12-06" @default.
• W2031240327 modified "2023-10-17" @default.
• W2031240327 title "Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO)" @default.
• W2031240327 cites W1605523334 @default.
• W2031240327 cites W1644299043 @default.
• W2031240327 cites W2012784647 @default.
• W2031240327 cites W2033779255 @default.
• W2031240327 cites W2045134790 @default.
• W2031240327 cites W2045424766 @default.
• W2031240327 cites W2053003998 @default.
• W2031240327 cites W2097698108 @default.
• W2031240327 cites W2098775844 @default.
• W2031240327 cites W2105765694 @default.
• W2031240327 cites W2110444464 @default.
• W2031240327 cites W2115330997 @default.
• W2031240327 cites W2115759102 @default.
• W2031240327 cites W2141393790 @default.
• W2031240327 cites W2144124503 @default.
• W2031240327 cites W2146384083 @default.
• W2031240327 cites W2149908785 @default.
• W2031240327 cites W2159459001 @default.
• W2031240327 cites W2318605753 @default.
• W2031240327 cites W4249219283 @default.
• W2031240327 doi "https://doi.org/10.1179/1973947813y.0000000147" @default.
• W2031240327 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24112786" @default.
• W2031240327 hasPublicationYear "2013" @default.
• W2031240327 type Work @default.
• W2031240327 sameAs 2031240327 @default.
• W2031240327 citedByCount "24" @default.
• W2031240327 countsByYear W20312403272014 @default.
• W2031240327 countsByYear W20312403272015 @default.
• W2031240327 countsByYear W20312403272016 @default.
• W2031240327 countsByYear W20312403272017 @default.
• W2031240327 countsByYear W20312403272018 @default.
• W2031240327 countsByYear W20312403272019 @default.
• W2031240327 countsByYear W20312403272020 @default.
• W2031240327 countsByYear W20312403272021 @default.
• W2031240327 countsByYear W20312403272022 @default.
• W2031240327 countsByYear W20312403272023 @default.
• W2031240327 crossrefType "journal-article" @default.
• W2031240327 hasAuthorship W2031240327A5016011343 @default.
• W2031240327 hasAuthorship W2031240327A5016695561 @default.
• W2031240327 hasAuthorship W2031240327A5028500628 @default.
• W2031240327 hasAuthorship W2031240327A5033702098 @default.
• W2031240327 hasAuthorship W2031240327A5033726162 @default.
• W2031240327 hasAuthorship W2031240327A5033820961 @default.
• W2031240327 hasAuthorship W2031240327A5037337957 @default.
• W2031240327 hasAuthorship W2031240327A5038018761 @default.
• W2031240327 hasAuthorship W2031240327A5044367089 @default.
• W2031240327 hasAuthorship W2031240327A5044883162 @default.
• W2031240327 hasAuthorship W2031240327A5045696675 @default.
• W2031240327 hasAuthorship W2031240327A5064627647 @default.
• W2031240327 hasAuthorship W2031240327A5074710198 @default.
• W2031240327 hasAuthorship W2031240327A5075330567 @default.
• W2031240327 hasAuthorship W2031240327A5075580269 @default.
• W2031240327 hasAuthorship W2031240327A5077193503 @default.
• W2031240327 hasAuthorship W2031240327A5082587759 @default.
• W2031240327 hasConcept C121608353 @default.
• W2031240327 hasConcept C126322002 @default.
• W2031240327 hasConcept C143998085 @default.
• W2031240327 hasConcept C197934379 @default.
• W2031240327 hasConcept C2775930923 @default.
• W2031240327 hasConcept C2776802502 @default.
• W2031240327 hasConcept C2777329042 @default.
• W2031240327 hasConcept C2777511904 @default.
• W2031240327 hasConcept C2777909004 @default.
• W2031240327 hasConcept C2778375690 @default.
• W2031240327 hasConcept C2778570526 @default.
• W2031240327 hasConcept C2779786085 @default.
• W2031240327 hasConcept C526805850 @default.
• W2031240327 hasConcept C530470458 @default.
• W2031240327 hasConcept C71924100 @default.
• W2031240327 hasConcept C90924648 @default.
• W2031240327 hasConceptScore W2031240327C121608353 @default.
• W2031240327 hasConceptScore W2031240327C126322002 @default.
• W2031240327 hasConceptScore W2031240327C143998085 @default.
• W2031240327 hasConceptScore W2031240327C197934379 @default.
• W2031240327 hasConceptScore W2031240327C2775930923 @default.
• W2031240327 hasConceptScore W2031240327C2776802502 @default.

• next